secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001493152-23-016659
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AgeX Q1 2023 net loss widens to $3.3M; cash only $0.3M; going concern flagged
-----------------------------------------------------------------------------

- Cash, cash equivalents and restricted cash totaled $0.3M as of March 31, 2023.
- Owed Juvenescence $33.6M in principal and origination fees; secured note line increased by $4M on May 9.
- Q1 revenue $10K (up from $5K YoY); operating expenses $2.2M vs $2.1M.
- Net loss attributable to AgeX $3.3M ($0.09 per share) vs $2.7M ($0.07) in prior year.
- Company expresses substantial doubt about ability to continue as a going concern.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/0001493152-23-016659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315223016659/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer